Abbott Laboratories (ABT) Non-Current Debt (2009 - 2026)

Abbott Laboratories has disclosed Non-Current Debt across 18 years of filings, most recently posting $29.6 billion for Q2 2026.

• In Q2 2026, Non-Current Debt rose 128.95% year-over-year to $29.6 billion; the TTM figure through Jun 2026 stood at $29.6 billion (up 128.95% YoY), while the FY2025 annual figure was $9.9 billion, down 29.94% from the prior year.
• Non-Current Debt came in at $29.6 billion for Q2 2026 at Abbott Laboratories, roughly flat from $29.6 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $29.6 billion in Q1 2026 to a low of $9.9 billion in Q4 2025.
• Average Non-Current Debt over 5 years is $15.7 billion, with a median of $14.5 billion recorded in 2023.
• Year-over-year, Non-Current Debt slipped 29.94% in 2025 and jumped 132.71% in 2026.
• Over 5 years, Non-Current Debt stood at $16.8 billion in 2022, then decreased by 12.48% to $14.7 billion in 2023, then fell by 3.77% to $14.1 billion in 2024, then slipped by 29.94% to $9.9 billion in 2025, then surged by 199.14% to $29.6 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $29.6 billion in Q2 2026, $29.6 billion in Q1 2026, and $9.9 billion in Q4 2025.